MedTrace Logo

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion

NCT04389359 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2021-03-08

No results posted yet for this study

Summary

The PROTECT open-label randomised basket trial will assess the effectiveness of hydroxychloroquine (HCQ) as chemoprophylaxis against COVID-19 in multiple vulnerable populations in the United Kingdom.

Conditions

Interventions

DRUG

Hydroxychloroquine Sulfate 200 MG

Hydroxychloroquine Sulfate administered orally for a maximum of 6 months. Doses population specific.

Sponsors & Collaborators

Principal Investigators

  • Thomas Hiemstra, PhD · Cambridge University Hospitals NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2021-08-31
Completion
2025-08-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04389359 on ClinicalTrials.gov